# Junta clínica — PT-pseudo_562159dc2cc6 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_562159dc2cc6",
  "pid": "PT-pseudo_562159dc2cc6",
  "task": 1,
  "psa": 9.9,
  "age": 48,
  "months": 3,
  "pirads": "2",
  "psad": 0.19,
  "psav": 0.31,
  "psap": 6.7,
  "vol": 50.0,
  "dre": "Normal",
  "bx": "None",
  "cspca": 0.6607788,
  "medhx": "Hypertension",
  "meds": "lisinopril, metoprolol",
  "notes": "PSA 9.9 ng/mL. PI-RADS 2. PSAD 0.19. Prostate volume 50 mL. csPCa 0.66.",
  "pmhx": [
    "Hypertension"
  ],
  "allergies": [],
  "vitals": {
    "weight": "73 kg",
    "height": "180 cm",
    "bmi": "22.5",
    "bp": "137/81 mmHg",
    "hr": "81 bpm",
    "smoking": "Ex-smoker (35 pack-yr, quit 2016)",
    "last_dental": "1 yr ago",
    "flu_vax": "Oct 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "28 Jan 2025",
  "enc_ref": "Dr. R. Visser (GP)",
  "enc_type": "Follow-up - PSA + MRI",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Persistent PSA elevation and recent multiparametric MRI prompt this clinical reassessment."
    },
    {
      "s": "History",
      "t": "Long-standing clinical tracking continues for fluctuating PSA values, first documented at 9.3 ng/mL during early 2024. A 48-year-old retired postal worker currently navigating a married life while residing independently, with his adult daughter serving as the main point of contact. Moderate lower urinary tract symptoms surface regularly, yielding an IPSS score of 15 out of 35, though he explicitly denies any pelvic discomfort or hematuria. Well-managed hypertension relies on lisinopril and metoprolol, with no recorded drug allergies. His tobacco use spans 35 pack-years, successfully discontinued back in 2016. Outside urological concerns, he attends physiotherapy for chronic lower back strain, visits a pain clinic for lingering shoulder issues, and recently finished a sleep clinic evaluation regarding suspected obstructive sleep apnoea. Alcohol remains completely absent from his routine, which otherwise features weekend hiking trips. Morning scheduling strictly aligns with his public transport availability."
    },
    {
      "s": "Physical examination",
      "t": "Per rectum: the prostate presents symmetrically with a smooth, firm consistency, lacking any palpable nodules or asymmetry, consistent with a normal digital rectal examination. Vital signs remain stable, recording a blood pressure of 137/81 mmHg and a regular heart rate of 81 bpm. General physical assessment proves entirely unremarkable, with no palpable lymphadenopathy or abdominal masses detected."
    }
  ],
  "occupation": "retired postal worker",
  "marital": "Married",
  "living": "Lives alone; adult daughter is primary contact",
  "next_of_kin": "Adult daughter (primary contact)",
  "recent_other": [
    "Physiotherapy — lower back, six sessions",
    "Sleep clinic — suspected obstructive sleep apnoea",
    "Pain clinic — chronic shoulder pain"
  ],
  "alcohol": "0 units / week (alcohol-free)",
  "exercise": "Hiking on weekends",
  "ipss": "IPSS score: 15/35 (moderate LUTS)",
  "admin": "Patient prefers morning appointments (public transport).",
  "mri_hospital": "Spaarne Gasthuis (Haarlem)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_562159dc2cc6
Task: 1

Encounter: Urology - outpatient on 28 Jan 2025.
Referrer: Dr. R. Visser (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 48-year-old male
  - PSA: 9.9 ng/mL
  - mpMRI — PI-RADS score: 2 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.19 ng/mL²
  - PSA velocity: 0.31 ng/mL/yr
  - Prior PSA: 6.7 ng/mL
  - Prostate volume: 50.0 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.6607788 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension
  - Problem list / PMHx: Hypertension
  - Current medication: lisinopril, metoprolol
  - Allergies: NKA
  - Additional notes: PSA 9.9 ng/mL. PI-RADS 2. PSAD 0.19. Prostate volume 50 mL. csPCa 0.66.

Vitals: weight 73 kg, height 180 cm, BMI 22.5, BP 137/81 mmHg, HR 81 bpm. Smoking: Ex-smoker (35 pack-yr, quit 2016).

Chief complaint: Persistent PSA elevation and recent multiparametric MRI prompt this clinical reassessment.

History: Long-standing clinical tracking continues for fluctuating PSA values, first documented at 9.3 ng/mL during early 2024. A 48-year-old retired postal worker currently navigating a married life while residing independently, with his adult daughter serving as the main point of contact. Moderate lower urinary tract symptoms surface regularly, yielding an IPSS score of 15 out of 35, though he explicitly denies any pelvic discomfort or hematuria. Well-managed hypertension relies on lisinopril and metoprolol, with no recorded drug allergies. His tobacco use spans 35 pack-years, successfully discontinued back in 2016. Outside urological concerns, he attends physiotherapy for chronic lower back strain, visits a pain clinic for lingering shoulder issues, and recently finished a sleep clinic evaluation regarding suspected obstructive sleep apnoea. Alcohol remains completely absent from his routine, which otherwise features weekend hiking trips. Morning scheduling strictly aligns with his public transport availability.

Physical examination: Per rectum: the prostate presents symmetrically with a smooth, firm consistency, lacking any palpable nodules or asymmetry, consistent with a normal digital rectal examination. Vital signs remain stable, recording a blood pressure of 137/81 mmHg and a regular heart rate of 81 bpm. General physical assessment proves entirely unremarkable, with no palpable lymphadenopathy or abdominal masses detected.

Patient info: retired postal worker; Married; Lives alone; adult daughter is primary contact.
Next of kin: Adult daughter (primary contact).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Hiking on weekends; IPSS score: 15/35 (moderate LUTS).

Recent other appointments: Physiotherapy — lower back, six sessions; Sleep clinic — suspected obstructive sleep apnoea; Pain clinic — chronic shoulder pain.
Admin: Patient prefers morning appointments (public transport).

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-CLASSIFIER

*statistical classifier; suggests a starting point, decides nothing* · vuelta 1

A classifier trained only to open the discussion, not to close it. Here is its bid.

SUGGESTION: NO BIOPSY   p(biopsy) = 0.50
  uncertainty  +/- 0.22 (95% CI 0.07-0.93); among patients it cannot tell apart the outcome was 1.00 of 1.00 mixed
  confidence   LOW — in this tier it was right 49% of the time over 43 labelled cases — barely better than a coin, so treat it as an opening bid and nothing more

It read ONLY these variables: PI-RADS, prior biopsy status, PSA, age, PSA density, DRE, prostate volume, number of problems on the list. Nothing else — not the mpMRI prose, not the PSA
trajectory, not the previous notes, not this patient's management plan. Values it could not
read for this patient: none.
Out-of-fold over 91 labelled cases (5x5 StratifiedKFold, out-of-fold): accuracy 0.714 against a
majority-class baseline of 0.615, AUC 0.789, F1(yes) 0.78.

The final call is the senior urologist's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: never biopsied. My criterion answers DEFER.

The criterion: sample when the mpMRI shows a PI-RADS 3 or higher lesion; defer at PI-RADS 1-2. In the labelled series this criterion matched the reading urologist in 24 of 24 cases in exactly this situation.

Like the classifier, I have read ONLY the visible panel — not the mpMRI prose, the PSA
trajectory, the previous notes or the laboratory panel. Departing from me needs a specific
finding from a document somebody actually opened, named out loud. Not a restatement of the
panel numbers I already used.

## Intervención 5 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The guideline suggests that a PI-RADS threshold of $\ge 3$ is used to trigger biopsy. "a PI-RADS threshold of $\u2265 3$ is used to trigger biopsy [135, 226, 264, 375]". This requires a decision based on the PI-RADS score.

WHAT THE CLASSIFIER'S BID DOES NOT SETTLE
The classifier's suggestion of "NO BIOPSY" is not sufficiently informed by the guideline because it ignores the PI-RADS threshold that the guideline uses to trigger biopsy. It fails to account for the fact that the patient has a PI-RADS 2 score, which falls below the threshold mentioned in the guideline.

WHAT WE STILL NEED
The mpMRI prose - PI-RADS score is 2, which is below the threshold of $\ge 3$ mentioned in the guideline, suggesting a decision based on this threshold.
The PSA density is $0.19 \text{ ng/mL}^2$, which is close to the $0.20 \text{ ng/mL/cc}$ mentioned in the guideline for omitting biopsy when MRI is negative.
The prior biopsy status is "None", which is a fact the guideline makes decisive regarding the need for a repeat biopsy.

## Intervención 6 — MODERATOR

*chairs the discussion; sets the verification plan and the open questions* · vuelta 1

This case hinges on whether the PI-RADS 2 score is sufficient to defer biopsy according to the EAU guideline, and we need to review the full MRI report to confirm the context.

Before anyone argues, this is what I want established, and by whom.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Determine the mpMRI prose, including lesion size and zone, to fully assess the PI-RADS 2 finding.
  psa_trend (get_psa_trend) -> Review the PSA trend to see if the velocity is relevant in conjunction with the PI-RADS score.
  previous_notes (get_previous_notes) -> Review previous notes to understand the management context and prior planning.

OPEN QUESTIONS for this conference — these are what the decision hangs on, and I expect them answered by name, not in general terms:
  Q1. What is the mpMRI prose regarding the lesion size and zone?

On the plan itself: Dropped 1 question(s) that asked for a value already printed on the panel: "Does the PSA density of $0.19 ext{ ng/mL}^2$ meet the guideline criteria for omitting biopsy when the MRI is negative?" — the room can read it off intervention 1.

## Intervención 7 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The mpMRI prose regarding the lesion size and zone is: "Volumetric assessment yields a gland size of 50.0 mL. T2-weighted sequences reveal a homogeneous peripheral zone, lacking focal signal drops or diffusion restriction on ADC maps. Mild nodular hyperplasia characterizes the transition zone, aligning with benign enlargement. Dynamic contrast phases exhibit no early or focal enhancement patterns. Seminal vesicles maintain normal caliber and signal intensity. There is no evidence of extraprostatic spread or suspicious nodal disease. The bladder wall presents smoothly, free of diverticula. IMPRESSION: Benign prostatic enlargement measuring 50.0 mL. No PI-RADS 3 or higher lesion identified. PI-RADS 2. PSA density: 0.19 ng/mL/mL. csPCa predicted probability 0.6607788."

psa_trend
The PSA trend review shows values: {"date": "Feb 2024", "val": 2.9}, {"date": "Aug 2024", "val": 4.9}, {"date": "Jan 2025", "val": 9.9}.

previous_notes
The previous notes review shows: [{"date": "03 Feb 2024", "author": "Dr. R. Visser (GP)", "text": "Initial laboratory screening in February 2024 flagged a PSA reading of 9.3 ng/mL, which triggered a repeat draw and urology referral. Follow-up values temporarily decreased to 6.7 ng/mL during August, before climbing back to 9.9 ng/mL. The most recent multiparametric MRI scans and updated chemistry panel have been dispatched for specialist assessment."}]

WHAT I DID NOT OPEN
I did not open the laboratory_results because the moderator did not specifically ask for it, and the panel data was sufficient for the current decision point.

WHAT THIS SUPPORTS
FOR sampling this patient now
The cohort criterion matched the reading urologist in 24 of 24 cases when the mpMRI showed a PI-RADS 3 or higher lesion.
The EAU guideline suggests a PI-RADS threshold of $\ge 3$ is used to trigger biopsy.

AGAINST sampling this patient now
The EXPERT-CLASSIFIER suggested NO BIOPSY with a p-value of 0.50.
The EXPERT-COHORT criterion suggests DEFER when the mpMRI shows a PI-RADS 1-2 lesion.

WHERE THIS LEANS
The MRI report confirms a PI-RADS 2 finding, which aligns with the EXPERT-COHORT's criterion for deferral and the EAU guideline's threshold. This leans towards deferral.
LEAN: defer

## Intervención 8 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The registrar successfully answered Q1 by providing the mpMRI prose, which confirmed a PI-RADS 2 finding and noted no PI-RADS 3 or higher lesion.

ALIGNMENT WITH THE CLASSIFIER
The retrieved evidence aligns with the EXPERT-COHORT's suggestion to defer, as the MRI confirmed a PI-RADS 2 finding, which is within the deferral range specified by that cohort criterion.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the mpMRI prose regarding the lesion size and zone? Answered by the Registrar via the radiology_report, which stated benign prostatic enlargement with a PI-RADS 2 finding.
Q2. Is the PI-RADS 2 score sufficient to defer biopsy according to the EAU guideline? Not answered by any intervention; the EAU expert noted the threshold is $\ge 3$.
Q3. Does the PSA density of $0.19 \text{ ng/mL}^2$ meet the guideline criteria for omitting biopsy when the MRI is negative? Not answered by any intervention.

WHAT CARRIES WEIGHT, AND WHY
The PI-RADS score is critical because the EAU guideline explicitly uses a threshold of $\ge 3$ to trigger biopsy, and the MRI confirmed a PI-RADS 2 finding. The prior biopsy status is also relevant as it is "None," which is a fact the guideline makes decisive. The PSA density is relevant as it is close to a guideline value for omission. The room has been leaning on the PI-RADS score and the EAU guideline, which both point toward deferral.

MY SUGGESTION TO THE CHAIR
I suggest deferral based on the PI-RADS 2 score falling below the EAU threshold of 3, which is supported by the cohort data.

VERDICT: ready | SUGGEST: defer | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 9 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: NO BIOPSY   (confidence: clear)

I defer biopsy because the mpMRI demonstrated a PI-RADS 2 finding, which falls below the EAU threshold of 3 for biopsy. This conclusion is strongly supported by the EXPERT-COHORT criterion, which matched the reading urologist in 24 of 24 cases with PI-RADS 1-2 lesions. The Registrar confirmed the PI-RADS 2 finding and noted no higher-risk lesions, which aligns with the guideline and cohort data.

What carried weight: age=noted, psa=important, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes
